Citi Appointed as Depositary Bank for Vicore Pharma Holding AB’s ADR Program

LONDON--(BUSINESS WIRE)--Citi Issuer Services, acting through Citibank N.A., has been appointed by Vicore Pharma Holding AB (“Vicore Pharma”), a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), to act as Depositary Bank for its sponsored Level 2 American Depositary Receipt (“ADR”) program.

Vicore Pharma’s ADRs trade on the Nasdaq Capital Market under the symbol “VCRE”. Each ADS represents ten ordinary shares of the company. Vicore Pharma’s underlying ordinary shares are listed and traded on the Nasdaq Stockholm Stock Exchange under the symbol “VICO”.

Commenting on the appointment, Dirk Jones, Head of Issuer Services at Citi, said: “We are committed to supporting Vicore Pharma with high quality services through our industry-leading ADR solutions. Our deep capital markets expertise and extensive global network enable us to facilitate seamless access to global capital markets for issuers like Vicore Pharma.”

Citi Issuer Services is a leading provider of depositary receipt services. With depositary receipt programs in over 65 markets, spanning equity and fixed-income products, Issuer Services leverages Citi’s global network to provide cross-border capital market access to issuers, intermediaries, and investors.

About Citi

Citi is a preeminent banking partner for institutions with cross-border needs, a global leader in wealth management and a valued personal bank in its home market of the United States. Citi does business in more than 180 countries and jurisdictions, providing corporations, governments, investors, institutions and individuals with a broad range of financial products and services.

Additional information may be found at www.citigroup.com | X: @Citi | LinkedIn: www.linkedin.com/company/citi | YouTube: www.youtube.com/citi | Facebook: www.facebook.com/citi